Theravance Bi supplements proxy in Zymeworks merger, faces suits
Theravance Biopharma said it added supplemental disclosures to its proxy in connection with the proposed merger with Zymeworks. It also confirmed three shareholder complaints tied to the deal.
Theravance Bi announced supplemental disclosures to its proxy and confirmed three shareholder complaints tied to the proposed merger with Zymeworks.Key Highlights:Original SEC Filing: Theravance Biopharma, Inc. [ TBPH ] - 8-K - Sep. 10, 2026This is an AI-powered summary. It may contain inaccuracies…